Natixis Advisors LLC purchased a new stake in Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 14,378 shares of the company's stock, valued at approximately $681,000.
Several other hedge funds have also bought and sold shares of KYMR. Bayesian Capital Management LP bought a new stake in Kymera Therapeutics in the 1st quarter valued at about $569,000. Bank of New York Mellon Corp boosted its stake in Kymera Therapeutics by 19.3% in the second quarter. Bank of New York Mellon Corp now owns 156,211 shares of the company's stock worth $4,663,000 after buying an additional 25,317 shares in the last quarter. Renaissance Technologies LLC bought a new stake in Kymera Therapeutics in the second quarter valued at approximately $4,271,000. E Fund Management Co. Ltd. lifted its position in Kymera Therapeutics by 391.2% in the second quarter. E Fund Management Co. Ltd. now owns 48,946 shares of the company's stock valued at $1,461,000 after purchasing an additional 38,981 shares during the last quarter. Finally, Healthcare of Ontario Pension Plan Trust Fund bought a new stake in Kymera Therapeutics in the second quarter valued at approximately $1,910,000.
Insiders Place Their Bets
In other news, Director Pamela Esposito sold 13,500 shares of the company's stock in a transaction on Tuesday, September 17th. The shares were sold at an average price of $48.28, for a total value of $651,780.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 15.82% of the stock is currently owned by company insiders.
Kymera Therapeutics Trading Up 1.9 %
KYMR traded up $0.88 during trading hours on Thursday, hitting $46.86. 388,380 shares of the company's stock were exchanged, compared to its average volume of 587,311. Kymera Therapeutics, Inc. has a 12-month low of $19.11 and a 12-month high of $53.27. The firm has a 50 day moving average of $46.92 and a 200 day moving average of $42.07. The firm has a market cap of $3.03 billion, a P/E ratio of -20.03 and a beta of 2.21.
Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last announced its earnings results on Thursday, October 31st. The company reported ($0.82) earnings per share for the quarter, topping the consensus estimate of ($0.83) by $0.01. Kymera Therapeutics had a negative net margin of 191.26% and a negative return on equity of 24.96%. The firm had revenue of $3.74 million for the quarter, compared to the consensus estimate of $10.34 million. During the same period in the prior year, the firm earned ($0.90) EPS. The firm's revenue for the quarter was down 20.9% on a year-over-year basis. As a group, research analysts expect that Kymera Therapeutics, Inc. will post -2.79 EPS for the current fiscal year.
Analyst Ratings Changes
KYMR has been the topic of several recent research reports. Truist Financial reaffirmed a "buy" rating and issued a $53.00 price target (down from $54.00) on shares of Kymera Therapeutics in a research note on Friday, November 1st. Morgan Stanley raised their price objective on Kymera Therapeutics from $45.00 to $49.00 and gave the stock an "equal weight" rating in a research note on Wednesday, November 6th. Wolfe Research raised Kymera Therapeutics from a "peer perform" rating to an "outperform" rating and set a $65.00 price objective on the stock in a research note on Monday, August 26th. Oppenheimer lifted their target price on Kymera Therapeutics from $52.00 to $56.00 and gave the company an "outperform" rating in a research note on Friday, September 27th. Finally, Wells Fargo & Company lifted their target price on Kymera Therapeutics from $30.00 to $38.00 and gave the company an "equal weight" rating in a research note on Monday, August 12th. Four research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $52.13.
View Our Latest Analysis on Kymera Therapeutics
Kymera Therapeutics Company Profile
(
Free Report)
Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.
Featured Stories
Before you consider Kymera Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kymera Therapeutics wasn't on the list.
While Kymera Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.